In short
Clinical trials are studying HSP-CAR19M in adults with certain B-cell non-Hodgkin lymphomas. These studies aim to assess safety, toxicity, and possible benefit of the treatment. The main target groups are people with relapsed or refractory large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.
Key points
- Clinical trials of HSP-CAR19M are studying adults with certain B-cell non-Hodgkin lymphomas, including relapsed or refractory large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma. The listed study is an interventional Phase 1/2 trial. Its main focus is safety, with early evaluation of efficacy in the expansion phase. The trial plans to enroll 40 participants. Overall, the data show an early-stage cancer study in a small group of patients with hard-to-treat disease.
Trial overview
The available trial is an interventional study, which means people receive a treatment that is being tested. It is studying HSP-CAR19M in adults with B-cell non-Hodgkin lymphoma.
The study is authorised and plans to enroll 40 participants.
Who the study is for
The trial is for adults with relapsed/refractory large B-cell non-Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma. Relapsed means the cancer came back after treatment, and refractory means it did not respond well to treatment.
These conditions are all types of B-cell non-Hodgkin lymphoma, which are cancers that start in B cells, a kind of white blood cell.
Study phase and design
This is a Phase 1/2 trial. Phase 1/2 studies first look closely at safety, then also look for early signs that the treatment may help.
The brief summary says the study is evaluating the safety, toxicity, and efficacy of autologous memory T cells that are expanded outside the body and genetically modified with a chimeric antigen receptor targeting CD19. In simple terms, the trial is testing a personalized cell therapy made from the patient’s own cells.
What the trial measures
The primary outcome is safety associated with infusion of HSP-CAR19M cells. Safety outcomes help researchers see whether the treatment can be given without causing unacceptable problems.
In the expansion phase, the study also evaluates safety and efficacy of HSP-CAR19M cell administration. Efficacy means how well the treatment works against the cancer.
Treatments used in the study
The intervention list includes HSP-CAR19M and several other drugs given by intravenous infusion. The trial data do not explain the full role of each listed drug, so the key point is that HSP-CAR19M is part of a treatment plan studied in this trial.
Intravenous infusion means a treatment is given through a vein, usually over time.
What the trial details mean for patients
For patients, this study is an early-stage attempt to learn whether HSP-CAR19M can be used safely in hard-to-treat B-cell lymphomas. The trial is not just looking at one disease, but at several related lymphoma types in adults.
Because the study is Phase 1/2 and has a small planned enrollment, it is mainly designed to gather early information rather than provide final proof of benefit.